Thursday and Friday were the big follow-up appointment days
as I stated before. We saw Dr. Ahmed,
the oncologist, on Thursday. She and Deb
went over the pathology report (which Deb got a copy of on Tuesday) and
discussed the genetic testing results (which she gave Deb a copy of) and much
of it was med-speak and if it didn’t go over my head, it certainly scraped my
scalp. But I do feel that I caught the
gist of it.
First of all, Dr. Ahmed stated that while it was up to the
radiological oncologist to confirm, she didn’t feel that radiation would be
necessary given all of the pathology results.
Let me just skip ahead at this point and say that we saw the
radiation oncologist, Dr. Yao, on Friday and she told Deb something to the
effect of “Nice meeting you, but I got nuthin’ for ya.” No, that wasn’t exactly what she said, but
you get the idea.
Let me repeat myself here.
No radiation.
This is definitely a load off of our minds. I didn’t want to run the risk of her turning
into She-hulk. That would be bad. Green isn’t her color.
So going back to Thursday, the other subject of talk with
Dr. Ahmed was the remaining course of therapy.
Deb will be going on Tamoxifen for the next 5 to 10 years. That much is a given. Everything else is in flux. The current accepted protocols for chemotherapy
and other treatment rely on things like the size of the tumor and whether there
are receptors on the cancer cells that respond to estrogen, or progesterone, or
HER-2 (Human Epidermal Growth Factor Receptor 2 – yeah, I had to Google
that). Deb’s tumor size was right on the
decision line, and she was estrogen receptor and HER-2 positive but
progesterone receptor negative, which is apparently out of the ordinary.
It isn’t that the research says to do this or do that for
someone of her age with her pathology, it’s that the research doesn’t
exist. Part of this is that it is unusual
for a diagnosis like this to be made so early – her tumor size was small
because her monitoring was so often that it was detected very early.
And chemo comes with the risk of some potentially nasty side
effects – not just the short-term annoyances of hair loss and weight gain
(surprised to hear gain instead of loss – I expected the other way around), but
neuropathy and cardiomyopathy (Google those yourselves if you wish).
Next week are second opinion appointments, and genetic
counseling is still to come…and we’re hopeful that then we’ll have a clearer
path to making a decision. But those
decisions will still likely be very difficult.
How do you know where to place the cut-off point on the risk/benefit
chart? What is the point of diminishing
returns? Which risks are simply too
great? How many licks does it take to
get to the Tootsie-Roll center of a Tootsie-Pop? (The world may never know.)
Meanwhile, healing from surgery continues. Fatigue and some pain and soreness remain the
biggest nuisances she faces. And a new
torture has been instituted in the form of in-home PT to improve arm range of
motion. At least I can truly sympathize
with that.